R33
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 83
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.230
- APICAL_JUNCTION+0.170
- MYC_TARGETS_V2+0.130
- MYOGENESIS+0.120
- BILE_ACID_METABOLISM+0.110
- INFLAMMATORY_RESPONSE+0.110
- IL6_JAK_STAT3_SIGNALING+0.080
- KRAS_SIGNALING_DN+0.080
- P53_PATHWAY+0.070
Top 10 suppressed
- PROTEIN_SECRETION-0.460
- MYC_TARGETS_V1-0.380
- E2F_TARGETS-0.320
- G2M_CHECKPOINT-0.310
- PANCREAS_BETA_CELLS-0.300
- MTORC1_SIGNALING-0.270
- ANDROGEN_RESPONSE-0.260
- PI3K_AKT_MTOR_SIGNALING-0.230
- MITOTIC_SPINDLE-0.210
- CHOLESTEROL_HOMEOSTASIS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_PN2CE34A | low-grade glioma | — | 0.817 |
| 2 | R109 | — | — | 0.792 |
| 3 | SRR8942953 | — | — | 0.777 |
| 4 | d406bb03-1a9a-4aa3-a1a8-4de5478b4701 | — | — | 0.762 |
| 5 | AUR-AER7-TTM4-A-1-1-R-A742-41 | — | E | 0.754 |
| 6 | MNG1087 | — | — | 0.754 |
| 7 | BS_G5QBBHDV | low-grade glioma | — | 0.748 |
| 8 | BS_77317DY4 | Med | Medulloblastoma | 0.748 |
| 9 | C3L-00083 | — | cohortMD2 | 0.746 |
| 10 | MDT-AP-1167 | Med | Medulloblastoma | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| MYOGENESIS | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.060 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.020 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.020 | Remibrutinib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |